New study for LBT's WoundVue prototype

Latest News

Australian medical technology company LBT Innovations (ASX:LBT) has entered a collaboration with Central Adelaide Local Health Network (CALHN) Vascular and Endovascular Services.

Under the collaboration, the network will use LBT’s novel WoundVue prototype device in the clinical trial, 'Predicting outcomes in patients with diabetic foot ulcers and effectiveness of interventions to improve outcomes'.

WoundVue is a hand held portable device that takes 2D and 3D images of chronic wounds to objectively monitor wound healing.

The technology behind WoundVue originates from LBT’s FDA Cleared APAS platform, where the core machine learning algorithms have been adapted to interpret tissue types and automatically provide surface area, volume and depth measurements.

Vascular surgeon Professor Rob Fitridge, Head of Vascular Surgery at CALHN and Lyell McEwin Hospital, and Professor of Vascular Surgery at the University of Adelaide, said, “Using WoundVue in this trial will provide us with reliable and objective data that will feed into our predictive model for amputations resulting from diabetic foot ulcers. Accurate and reproducible measurements are required for any clinical decision support system, especially in the context of this trial where these data will be used to predict the likelihood of surgical intervention. We are enthusiastic about working closely with LBT in this trial and believe there is a real clinical unmet need that the WoundVue device can address.”

According to LBT CEO and managing director Brent Barnes, “This collaboration is the logical next step having recently completed the proof-of-principle work developing our core algorithms in automatic tissue identification and delivering a prototype device. Development of validated medical devices in a regulated environment takes time. We are excited to collaborate with Professor Fitridge and his team to have the WoundVue prototype device being used in a clinical setting that will allow for further development of our core technology.”